Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

5.130 +0.090 (+1.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,668,655
Open 5.050
Bid (Size) 5.130 (1)
Ask (Size) 5.300 (2)
Prev. Close 5.040
Today's Range 5.000 - 5.190
52wk Range 4.020 - 37.13
Shares Outstanding 98,384,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:FATE Long Term Investor Alert: Investigation of Potential Wrongdoing at Fate Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 05/24/2023 -- An investigation was announced for investors in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
Where Fate Therapeutics Stands With Analysts
 
Via Benzinga

Performance

YTD
-49.56%
-49.56%
1 Month
-12.16%
-12.16%
3 Month
-14.64%
-14.64%
6 Month
-73.36%
-73.36%
1 Year
-78.24%
-78.24%

More News

Read More
Fate Therapeutics: Q1 Earnings Insights
Via Benzinga
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Earnings Preview
Via Benzinga
$1.7M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
15 Analysts Have This to Say About Fate Therapeutics
Via Benzinga
Expert Ratings for Fate Therapeutics
Via Benzinga
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
From The Rosen Law Firm, P.A.
Via Business Wire
FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:FATE Investor Notice: Deadline on March 22, 2023 in Lawsuit Against Fate Therapeutics, Inc
Via SBWire
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Days to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
From The Rosen Law Firm PA
Via GlobeNewswire
Fate Therapeutics to Present at Upcoming March Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.